Ten stocks soared higher on Wednesday, mirroring a robust broader market performance, as investors took heart from a flurry of company-specific developments.
On Wall Street, all three major indices finished in the green, led by the Nasdaq, up 1.54 percent, followed by the Dow Jones, jumping 1.31 percent, and the S&P 500, rising 1.08 percent.
Indices aside, this article focuses on the 10 top-performing names on Wednesday and breaks down the reasons behind their gains.
To come up with the list, we considered the stocks with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Mizuno K on Pexels
10. POET Technologies Inc. (NASDAQ:POET)
POET Technologies snapped a three-day losing streak on Wednesday, climbing 13.08 percent to close at $14.78 apiece, after announcing an aggressive plan to expand its wafer manufacturing capabilities by 10x by 2027.
In an updated report, POET Technologies Inc. (NASDAQ:POET) said that it is currently in the process of expanding capacity “by roughly tenfold” in both wafer production and optical engine assembly.
“This expansion is being driven by the agreement we announced last week with Lumilens as well as other high-volume opportunities that are near fruition. In parallel with our manufacturing scale-up, we have accelerated the hiring of engineering, technical, and management talent, bringing our total headcount to more than 115 globally. We have also expanded our Singapore lab and office footprint by nearly three times compared to last year and now have 20,000 square feet of assembly space in Malaysia,” POET Technologies Inc. (NASDAQ:POET) Chairman and CEO Suresh Venkatesan.
The company recently bagged a new supply deal with Lumilens Inc. with the potential to generate $500 million in revenues over the next five years.
It is also setting its sights on acquiring and partnering with companies that could help strengthen its engineering capabilities, broaden its product portfolio, and enhance strategic technologies and components.
In line with the expansion plan, POET Technologies Inc. (NASDAQ:POET) earlier this week successfully raised $400 million in fresh funds from the sale of over 19 million common shares and warrants exercisable for the same size, to a single institutional investor. The shares were priced at $21 apiece, while the warrants are exercisable at $26.25 each, or a 25 percent premium over the selling price of the shares.
9. USA Rare Earth Inc. (NASDAQ:USAR)
USA Rare Earth rebounded on Wednesday, soaring 13.05 percent to finish at $22.57 apiece, as investors resorted to bargain-hunting while repositioning portfolios amid uncertainties over a rare earth deal between the US and China.
The rally was a bounce from seven straight days of volatility and losses that easily slashed the company’s share price by 25 percent, supported by the lack of concrete developments on rare earths between the US and China.
Last week, President Donald Trump met with his Chinese counterpart, Xi Jinping, to discuss key areas to resolve and work on, but developments on rare earths made little progress.
For USA Rare Earth Inc. (NASDAQ:USAR), easing of Chinese restrictions and any potential resolution between the two countries will generally be detrimental to growth, since the company has been largely benefiting from Washington’s push to secure a domestic supply chain for rare earths and critical minerals.
If tensions ease and Chinese supply becomes more accessible to the global market, concerns could emerge over reduced urgency for domestic sourcing.
In other news, USA Rare Earth Inc. (NASDAQ:USAR) last month successfully acquired rare earth miner Serra Verde Group for $2.8 billion.
Serra Verde owns the Pela Ema rare earth mine and processing plant in Goiás, Brazil, and will be acquired for a combination of $300 million cash and more than 126.8 million USAR shares.
The transaction is expected to close in the third quarter of the year, subject to customary closing conditions and regulatory approvals.
8. Enphase Energy Inc. (NASDAQ:ENPH)
Enphase Energy rebounded by 13.67 percent on Wednesday to close at $53.15 apiece, as investors cheered Goldman Sachs’ reaffirmation of a bullish stance for its stock and raising of its price target by double-digits.
In a market note, Goldman Sachs upgraded its price target for Enphase Energy Inc. (NASDAQ:ENPH) by 11.8 percent to $57 from $51 previously, while maintaining a “buy” recommendation. The price marked a 7.2 percent upside potential from its latest closing price.
The positive coverage came amid the looming July 4 deadline for a federal solar tax credit, under which, projects must begin construction and equipment must be safely harbored by the deadline for developers to qualify for a 30-percent incentive. This is expected to boost sales of solar and technology companies on the expectation that customers would scramble to place their orders prior to the deadline to qualify for the incentive.
In other news, Enphase Energy Inc. (NASDAQ:ENPH) on Monday unveiled a new PowerMatch technology for two IQ Battery systems—a 5P and a 10c—which intelligently adjust IQ battery operations to match a home’s real-time power needs.
The 10C variant is available for sale in the US and Puerto Rico, while the 5P is now for sale across North America and select countries in Central America and the Caribbean.
Enphase Energy Inc. (NASDAQ:ENPH) said that the two products would help deliver more usable energy, improved efficiency, and long-term savings for its customers.
7. Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while positioning portfolios ahead of the launch of its autoimmune disease treatment.
In an updated report, Roivant Sciences Ltd. (NASDAQ:ROIV) said that it swung to an attributable net income of $302.99 million from a $206.47 million attributable net loss in the same period last year, thanks to a $415 million operating income, which reversed a $284.96 million operating loss in the same period.
Revenues, on the other hand, fell by 66.7 percent to $2.52 million from $7.57 million in the same quarter last year.
Looking ahead, Roivant Sciences Ltd. (NASDAQ:ROIV) is targeting to commercially launch by the end of September its oral treatment, brepocitinib, to treat severe and rare autoimmune conditions.
Roivant Sciences Ltd. (NASDAQ:ROIV) said that the Food and Drug Administration has officially accepted its new drug application for the therapy, with an assigned target action date in the third quarter of the year.
6. Arm Holdings PLC (NASDAQ:ARM)
Arm Holdings extended its winning streak to a third straight day on Wednesday to hit a new all-time high, as investors continued to take heart from an investment firm’s highly optimistic stance for its stock, saying that profits are expected to rocket fivefold by 2030.
In intra-day trading, the stock climbed to its highest price of $259.44 before trimming gains to finish the session just up by 15.05 percent at $256.73 apiece.
In a market note, Bernstein assigned an outperform rating on shares of Arm Holdings PLC (NASDAQ:ARM), alongside a price target of $300, or an implied 16.8 percent upside potential from its latest closing price.
The coverage was based on the belief that the company stands to largely benefit from the renaissance of CPUs for agentic AI, given the rapid shift from chatbot to AI agents.
Bernstein also noted that Arm Holdings PLC (NASDAQ:ARM) is expected to capture a fourfold increase in CPU market share over the next four years to hit $137 billion.
“Arm stands out in server CPUs given its unparalleled power efficiency,” Bernstein said.
In other news, Arm Holdings PLC (NASDAQ:ARM) reported a 49 percent jump in its net income in the fourth quarter of fiscal year 2026 to $313 million from $210 million in the same period last year. Revenues also increased by 20 percent to $1.49 billion from $1.241 billion.
For the first quarter of fiscal year 2027 ending June, the company has set a revenue outlook of $1.26 billion, plus or minus $50 million. This would imply a 19.6 percent jump from the $1.053 billion reported in the same period a year earlier.
While we acknowledge the potential of ARM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARM and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the other 5 Stocks With Insane Returns Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
